All In Biotech

Drug Trial Radar · NCT06780098

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

May 28, 2025

Primary completion

Mar 2, 2032

Study completion Mar 2, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body. Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC. Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goals of this study are to learn about: * The cancer response to the study treatments compared to chemotherapy * The safety of the study treatments and if people tolerate them This study is one of the substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Conditions

  • Lung Neoplasm

Interventions

  • R-DXDBiological

    IV Infusion

  • I-DXDBiological

    IV Infusion

  • DocetaxelDrug

    IV Infusion

  • Rescue MedicationsDrug

    Participants receive rescue medications consisting of a combination regimen to include corticosteroids with a 5-hydroxytryptamine subtype 3 receptor antagonist and/or a neurokinin-1 receptor antagonist, all per approved product label and following institutional standards or local guidelines.

  • Rescue MedicationDrug

    Participants are premedicated with corticosteroids per approved product label and following institutional standards or local guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 81 months
  2. Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 81 months
  3. Number of participants who discontinue study intervention due to an AETime frame: Up to approximately 81 months

Locations

46 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Kentucky Chandler Medical Center ( Site 0019)

    Lexington, Kentucky · Recruiting

  • MedStar Franklin Square Medical Center ( Site 0033)

    Baltimore, Maryland · Recruiting

  • Texas Oncology - DFW ( Site 8003)

    Dallas, Texas · Recruiting

  • Virginia Cancer Specialists (VCS) ( Site 0408)

    Fairfax, Virginia · Recruiting

  • Centro de Estudios Clínicos SAGA ( Site 0161)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Fundación Arturo López Pérez ( Site 0160)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0162)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Cancer Hospital ( Site 0301)

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital ( Site 0304)

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Provincial Cancer Hospital ( Site 0310)

    Fuzhou, Fujian, China · Recruiting

  • Guangxi Medical University Cancer Hospital ( Site 0303)

    Nanning, Guangxi, China · Recruiting

  • Henan Cancer Hospital ( Site 0311)

    Zhengzhou, Henan, China · Recruiting

  • Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 0309)

    Nanjing, Jiangsu, China · Recruiting

  • Shanghai Chest Hospital ( Site 0308)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital ( Site 0300)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Charite-Universitaetsmedizin Berlin ( Site 0191)

    Berlin, Germany · Recruiting

  • UniversitaetsklInikum Tuebingen ( Site 0192)

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • European Interbalkan Medical Center-Oncology Department ( Site 0205)

    Thessaloniki, Greece · Recruiting

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)

    Athens, Attica, Greece · Recruiting

  • F. THERAPIS GENERAL ( Site 0206)

    Athens, Attica, Greece · Recruiting

  • Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063)

    Kecskemét, Bács-Kiskun county, Hungary · Recruiting

  • Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)

    Győr, Győr-Moson-Sopron, Hungary · Recruiting

  • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)

    Szolnok, Jász-Nagykun-Szolnok, Hungary · Recruiting

  • Rambam Health Care Campus ( Site 0076)

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center ( Site 0075)

    Jerusalem, Israel · Recruiting

  • Meir Medical Center ( Site 0071)

    Kfar Saba, Israel · Recruiting

  • Rabin Medical Center ( Site 0074)

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center ( Site 0070)

    Ramat Gan, Israel · Recruiting

  • Sourasky Medical Center ( Site 0077)

    Tel Aviv, Israel · Recruiting

  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)

    Florence, Italy · Recruiting

  • IRCCS Ospedale San Raffaele ( Site 0171)

    Milan, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)

    Roma, Italy · Recruiting

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153)

    Poznan, Greater Poland Voivodeship, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)

    Gdansk, Pomeranian Voivodeship, Poland · Recruiting

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0152)

    Koszalin, West Pomeranian Voivodeship, Poland · Recruiting

  • Hospital Universitario Quiron Madrid ( Site 0091)

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen Macarena ( Site 0094)

    Seville, Spain · Recruiting

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.